SCHEMBL5048938

SCHEMBL5048938

Cc1c(C(=O)NCC2CCCCC2)cc(-c2csc(-c3cnccn3)n2)n1CC(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 4/20 0.46
KLK1 P06870 2/20 0.46
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CNR1 P21554 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CPT2 P23786 1/20 0.36
CPT1A P50416 1/20 0.36
CPT1B Q92523 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
CNR2 P34972 3/20 0.35
PSMB11 A5LHX3 1/20 0.35
PSMA7 O14818 1/20 0.35
PSMB1 P20618 1/20 0.35
PSMA1 P25786 1/20 0.35
PSMA2 P25787 1/20 0.35
PSMA3 P25788 1/20 0.35
PSMA4 P25789 1/20 0.35
PSMB8 P28062 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044141 0.91 KLKB1 (0.48) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5043868 0.88 KLKB1 (0.46) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5039321 0.87 KLKB1 (0.45) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5045879 0.86 KLKB1 (0.44) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5043894 0.84 KLKB1 (0.47) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5048580 0.82 CHRM1 (0.44) CNR1CNR2
SCHEMBL5044584 0.82 KLKB1 (0.43) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5044887 0.82 KLKB1 (0.47) KLKB1KLK1SMN1; SMN2
SCHEMBL5039559 0.82 KLKB1 (0.46) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL6069189 0.82 KLKB1 (0.46) KLKB1KLK1HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885KLK1 3547/4885HDAC1 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.